Literature DB >> 1598871

Left ventricular dysfunction due to atrial fibrillation in patients initially believed to have idiopathic dilated cardiomyopathy.

M Grogan1, H C Smith, B J Gersh, D L Wood.   

Abstract

Ten patients aged 22 to 80 years (median 57) with severe left ventricular (LV) dysfunction and atrial fibrillation (AF) with rapid ventricular response were evaluated after therapy. Because most patients were unaware of their arrhythmia, duration was usually unknown. All patients had heart failure symptoms; 9 presented with New York Heart Association class III or IV disability, and 1 with class II disability. Initial LV ejection fraction ranged from 12 to 30% (median 25). No patient had symptomatic coronary artery disease (4 underwent angiography). Myocarditis and infiltrative processes were excluded by biopsy in 5 patients. All patients were considered initially to have idiopathic dilated cardiomyopathy with secondary AF. Ventricular rate was controlled in all patients, with sinus rhythm restored in 5. At follow-up (median 30 months, range 3 to 56), all patients were asymptomatic. LV ejection fraction after treatment ranged from 40 to 64% (median 52). It is concluded that in some patients initially considered to have idiopathic dilated cardiomyopathy, AF with rapid ventricular response may be the primary cause rather than the consequence of severe LV dysfunction. LV dysfunction may be completely reversible with ventricular rate control.

Entities:  

Mesh:

Year:  1992        PMID: 1598871     DOI: 10.1016/0002-9149(92)90705-4

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  80 in total

Review 1.  Transthoracic and transesophageal echocardiography in atrial fibrillation.

Authors:  C Stöllberger
Journal:  J Thromb Thrombolysis       Date:  1999-01       Impact factor: 2.300

Review 2.  Chronic and paroxysmal atrial fibrillation: course, prognosis, and stroke risk.

Authors:  T E Cuddy
Journal:  J Thromb Thrombolysis       Date:  1999-01       Impact factor: 2.300

Review 3.  Physiology and pathophysiology of the atria: its role in atrial fibrillation.

Authors:  J Godtfredsen
Journal:  J Thromb Thrombolysis       Date:  1999-01       Impact factor: 2.300

Review 4.  Clinical relevance of silent atrial fibrillation: prevalence, prognosis, quality of life, and management.

Authors:  I Savelieva; A J Camm
Journal:  J Interv Card Electrophysiol       Date:  2000-06       Impact factor: 1.900

5.  Atrial Fibrillation.

Authors: 
Journal:  Curr Treat Options Cardiovasc Med       Date:  2000-08

Review 6.  Implication from randomized trials of rate and rhythm controls on management of patients with persistent atrial fibrillation.

Authors:  Vincent E Hagens; Dirk J Van Veldhuisen; Harry J G M Crijns; Isabelle C van Gelder
Journal:  Ann Noninvasive Electrocardiol       Date:  2006-04       Impact factor: 1.468

Review 7.  Mechanisms underlying the development of atrial arrhythmias in heart failure.

Authors:  Vias Markides; Nicholas S Peters
Journal:  Heart Fail Rev       Date:  2002-07       Impact factor: 4.214

Review 8.  Symptoms and functional status of patients with atrial fibrillation: state of the art and future research opportunities.

Authors:  Michiel Rienstra; Steven A Lubitz; Saagar Mahida; Jared W Magnani; João D Fontes; Moritz F Sinner; Isabelle C Van Gelder; Patrick T Ellinor; Emelia J Benjamin
Journal:  Circulation       Date:  2012-06-12       Impact factor: 29.690

Review 9.  Maintaining stability of sinus rhythm in atrial fibrillation: antiarrhythmic drugs versus ablation.

Authors:  Gerald V Naccarelli; John Hynes; Deborah L Wolbrette; Luna Bhatta; Mazhar Khan; Jerry Luck
Journal:  Curr Cardiol Rep       Date:  2002-09       Impact factor: 2.931

10.  Estimation of left ventricular contractile performance in atrial fibrillation: experimental and clinical studies.

Authors:  R Tanaka; M Tomita; T Noda; K Kagawa; K Nishigaki; M Yamaguchi; A Kunishima; H Fujiwara
Journal:  Heart Vessels       Date:  1998       Impact factor: 2.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.